Skip to content
Home
Technology
Pipeline
Our Companies
Leadership
Leadership Voices
News & Events
Join Us
Contact
News & Events
Our latest news
[image placeholder – do not delete]
Select Company
All
Altavant
Enzyvant
Myovant
Spirovant
Sumitovant
Urovant
December 23, 2020
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
November 24, 2020
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
November 12, 2020
Sumitovant Biopharma and Urovant Sciences Announce Sumitovant’s Acquisition of Remaining Stake in Urovant
October 07, 2020
Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
August 13, 2020
Urovant Sciences Reports Fiscal First Quarter 2020 Results
June 18, 2020
Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
June 18, 2020
Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
May 27, 2020
Urovant Sciences Appoints James Hindman to Board of Directors
May 26, 2020
Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference
May 14, 2020
Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting
1
2
3
…
5
Next »